Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Vaccine From Novavax Is 89.3% Effective

By Cory Renauer - Updated Jan 29, 2021 at 10:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Results of a U.K. study suggest that an easy-to-distribute COVID-19 vaccine from Novavax is effective against the new variant.

A small company that's been developing new vaccines since Reagan was President, Novavax (NVAX 7.24%) announced its first late-stage clinical trial victory on Thursday afternoon. The company's COVID-19 vaccine candidate, NVX-CoV2373, reduced volunteers' chances of getting COVID-19 by 89.3% compared to a placebo. 

A smiling medical professional with a face mask pulled down beneath their chin.

Image source: Getty Images.

Novavax's first phase 3 clinical trial win comes from a 15,000-patient study in the U.K. A majority of the positive cases reported were of the now-predominant U.K. variant. NVX-CoV2373 appears just as effective at preventing the U.K. variant as the original coronavirus strain.

Investigators ran an interim analysis after 62 participants tested positive for COVID-19. All but six of them were in the placebo group. With a 95% confidence interval adjustment, that works out to an 89.3% efficacy rate overall.

Of the aforementioned 62 cases, 32 had the U.K. strain, 24 had the original strain, and six were unknown. Extrapolating from this limited sample, it looks like NVX-CoV2373 is 85.6% effective against the U.K. variant and 95.6% effective against the original recipe. 

Unfortunately for those of us in the U.S., the Food and Drug Administration isn't willing to review an emergency use authorization application without results from a mostly domestic phase 3 study. The company has randomized over 16,000 patients in a North American trial designed to meet the FDA's requirements. It has a total enrollment goal of 30,000 patients.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$61.29 (7.24%) $4.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.